Skip to main content
. 2015 Dec;5(6):322–331. doi: 10.1177/2045125315606027

Table 3.

Adverse events reported in 10% or higher of patients in any group (safety population).

Adverse event, n (%) Lurasidone 20 mg/day(n = 71) Lurasidone 40 mg/day(n = 67) Lurasidone 80 mg/day(n = 71) Haloperidol 10 mg/day(n = 72) Placebo (n = 72)
At least one adverse event 53 (74.6) 57 (85.1) 56 (78.9) 63 (87.5) 57 (79.2)
Headache 16 (22.5) 15 (22.4) 16 (22.5) 14 (19.4) 23 (31.9)
Sedation 7 (9.9) 11 (16.4) 14 (19.7) 14 (19.4) 6 (8.3)
Dyspepsia 10 (14.1) 8 (11.9) 10 (14.1) 7 (9.7) 9 (12.5)
Nausea 8 (11.3) 7 (10.4) 13 (18.3) 4 (5.6) 8 (11.1)
Akathisia 4 (5.6) 9 (13.4) 13 (18.3) 14 (19.4) 7 (9.7)
Vomiting 5 (7.0) 5 (7.5) 12 (16.9) 4 (5.6) 5 (6.9)
Somnolence 4 (5.6) 4 (6.0) 8 (11.3) 9 (12.5) 4 (5.6)
Fatigue 5 (7.0) 2 (3.0) 9 (12.7) 6 (8.3) 3 (4.2)
Agitation 6 (8.5) 7 (10.4) 2 (2.8) 2 (2.8) 3 (4.2)
Insomnia 5 (7.0) 5 (7.5) 4 (5.6) 10 (13.9) 4 (5.6)
Extrapyramidal disorder 2 (2.8) 4 (6.0) 4 (5.6) 15 (20.8) 3 (4.2)
Constipation 2 (2.8) 1 (1.5) 6 (8.5) 3 (4.2) 9 (12.5)
Dystonia 0 (0) 2 (3.0) 2 (2.8) 11 (15.3) 1 (1.4)